Oliver Fetzer has served as CEO and board member of Viridos, a biotechnology company dedicated to the energy transition, since November 2014. Oliver is passionate about biotechnology’s ability to make the world a better place. At Viridos, this translates into bioengineering microalgae to produce algae oil that can be refined into low-carbon transportation fuels. Viridos’ bioengineering technology provides the scalable and sustainable fuel alternative we need to reduce greenhouse gas emissions.
Previously, Oliver served for five years as President and CEO of Cerulean Pharma, a biotechnology company that developed nanoparticle cancer medicines. Under his leadership, Cerulean grew from a pre-clinical platform company into a publicly traded clinical-development-stage company.
Earlier, Oliver spent five years at Cubist Pharmaceuticals, a biotechnology company that targeted antibacterial drug resistance by developing and commercializing one of the most successful i.v. antibiotics in history. At Cubist, he was Senior Vice President, Corporate Development and Chief Business Officer, and subsequently Senior Vice President, Research & Development and Corporate Development.
Oliver began his career at the Boston Consulting Group (BCG), a global management consulting firm, where he was based in Boston, Auckland, and Munich and advanced over nine years to become Partner and Managing Director.
He has served on the boards of publicly traded companies Tecan since 2011, Arena Pharmaceuticals from 2017 to 2022, Cerulean Pharma from 2009 to 2014, and Auxilium Pharmaceuticals from 2005 to 2015.
Oliver received a BS in Biochemistry from the College of Charleston, a PhD in Pharmaceutical Sciences from the Medical University of South Carolina, and an MBA from Carnegie Mellon University.